Pregnancy Outcomes of Mothers with Detectable CMV-Specific IgM Antibodies: A Three-Year Review in a Large Irish Tertiary Referral Maternity Hospital

Table 1

Overview of the CMV IgM positive results in patients at the Rotunda Hospital between 2012 and 2014.

622 CMV IgM tests sent from 572 patients
↓		↓
37 patients with positive CMV IgM (Architect)		535 patients with negative CMV IgM
↓
34 obstetric patients included in analysis; 3 nonobstetric patients removed
↓
CMV IgM confirmed on second platform (Vidas)?		→	No ()
↓			↓
Yes ()			↓
↓	↓	↓	↓
Avidity ≤ 0.4; (Acute infection <3 months ago)	Avidity >0.4 and <0.65; (Date of infection uncertain)	Avidity ≥0.65; (Previous infection acquired > 3 months ago)	Cross reactivity; (CMV IgM positivity not confirmed in 2 assays)
↓	↓	↓	↓
↓	↓	↓	↓
, severe laboratory confirmed congenital CMV disease with neurological abnormalities (maternal CMV IgM tests sent at 11 and 15 weeks’ gestation, resp.); , IUGR but CMV not detected in urine at birth (maternal CMV IgM test sent at 30 weeks); , normal but CMV not detected in urine at birth (maternal CMV IgM test sent at 31 weeks’ gestation)	, intrauterine death; , lost to follow-up	, healthy live-born (3 neonates did not have CMV detected in urine, 1 was not tested); , stillborn; , multiple congenital anomalies detected in utero and lost to follow-up; , early neonatal death due to prematurity at 26 wk gestation (twins); , miscarriage	, healthy live-born pregnancies (1 set of twins); , Intrauterine death; , miscarriage; , went abroad for delivery